08:00 , Dec 20, 2010 |  BioCentury  |  Emerging Company Profile

BigDNA: Fewer Shots on Goal

Most marketed HBV vaccines, as well as DNA vaccines in development for the disease, require multiple booster injections or an adjuvant to trigger an immune response. BigDNA Ltd. believes its bacteriophage-delivered DNA vaccine will require...
07:00 , May 17, 2010 |  BioCentury  |  Regulation

Adventitious Detection

Now that an academic researcher using new sequencing technology has detected foreign viral DNA in a live attenuated rotavirus vaccine, vaccine developers would be smart - and may eventually be required - to test all...
07:00 , May 4, 2009 |  BioCentury  |  Product Development

Vaccine Manufacturing Technologies

Vaccine Manufacturing Technologies Company Vaccine manufacturing technology Avir Green Hills Biotechnology AG deltaFLU technology uses tissue cultures to produce vaccine Bacilligen Inc. Bacterial cells Baxter International Inc. (NYSE:BAX) Vero cells Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL) /...
07:00 , May 4, 2009 |  BioCentury  |  Product Development

Opportunity in Crisis

The scramble to create and mass produce vaccines to combat the outbreak of H1N1 swine influenza is exposing the limitations of global pandemic preparedness and, in the process, highlighting scientific, technological and commercial opportunities for...
08:00 , Jan 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Infectious disease Respiratory syncytial virus (RSV) Not applicable Mouse studies suggest that a vaccine derived from bacillus Calmette-Guérin (BCG) could...
08:00 , Jan 8, 2009 |  BC Innovations  |  Targets & Mechanisms

Besieging RSV

A team of U.S. and Chilean researchers has reported that a vaccine derived from bacillus Calmette-Guérin could prevent respiratory syncytial virus infection in infants and children. 1 It's unlikely the vaccine would take market share...
07:00 , Mar 24, 2008 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Corporate Profile Bacilligen Inc. Rockville, Md. Technology: Recombinant Mycobacteria (rMB), Bacilligen Vector System (BVS), High Valence Immunogen Display (HVID) Disease focus: Infectious, cancer Clinical status: Preclinical Founded: 2006 by Steve Bende and David Hone University...
07:00 , Mar 24, 2008 |  BioCentury  |  Emerging Company Profile

Bacilligen: Building on bacteria

Bacilligen Inc. . has three bacteria-based technology platforms that it believes confer safety, efficacy and manufacturing advantages when developing vaccines and therapeutics for infectious diseases and cancer, as well as allowing rapid manufacturing of therapeutic...